Shen Yanting, Xu Huan, Long Manmei, Guo Miaomiao, Li Peizhang, Zhan Ming, Wang Zhong
Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Department of Pathology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Front Oncol. 2021 Nov 5;11:761643. doi: 10.3389/fonc.2021.761643. eCollection 2021.
Existing prognostic risk assessment strategies for prostate cancer (PCa) remain unsatisfactory. Similar treatments for patients at the same disease stage can lead to different survival outcomes. Thus, we aimed to explore a novel immune landscape-based prognostic predictor and therapeutic target for PCa patients.
A total of 490 PCa patients from The Cancer Genome Atlas Project (TCGA) cohort were analyzed to obtain immune landscape-based prognostic features. Then, analyses at different levels were performed to explore the relevant survival mechanisms, prognostic predictors, and therapeutic targets. Finally, experimental verification was performed using a tissue microarray (TMA) from 310 PCa patients. Furthermore, a nomogram was constructed to provide a quantitative approach for predicting the prognosis of patients with PCa.
The immune landscape-based risk score (ILBRS) was obtained. Then, VAV1, which presented a significant positive correlation with Treg infiltration and ILBRS, was screened and identified to be significantly related to the prognosis of PCa. Finally, experimental verification confirmed the prognostic value of VAV1 for PCa prognosis at the protein level.
VAV1 has the potential to be developed as an immune landscape-based PCa prognostic predictor and therapeutic target and will help improve prognosis by enabling the selection of individualized, targeted therapy.
现有的前列腺癌（PCa）预后风险评估策略仍不尽人意。处于相同疾病阶段的患者接受相似治疗却可能导致不同的生存结果。因此，我们旨在探索一种基于免疫图谱的新型前列腺癌患者预后预测指标和治疗靶点。
对来自癌症基因组图谱计划（TCGA）队列的490例前列腺癌患者进行分析，以获得基于免疫图谱的预后特征。然后，在不同层面进行分析，以探索相关的生存机制、预后预测指标和治疗靶点。最后，使用来自310例前列腺癌患者的组织微阵列（TMA）进行实验验证。此外，构建了列线图，为预测前列腺癌患者的预后提供一种定量方法。
获得了基于免疫图谱的风险评分（ILBRS）。然后，筛选并鉴定出与调节性T细胞浸润和ILBRS呈显著正相关的VAV1，其与前列腺癌的预后显著相关。最后，实验验证在蛋白质水平证实了VAV1对前列腺癌预后的预测价值。
VAV1有潜力被开发成为基于免疫图谱的前列腺癌预后预测指标和治疗靶点，并将通过实现个体化靶向治疗的选择来帮助改善预后。
